Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Dasatinib + Vemurafenib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colorectal cancer | sensitive | Dasatinib + Vemurafenib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, treatment with the combination of Zelboraf (vemurafenib) and Sprycel (dasatinib) induced apoptosis and cell cycle arrest, inhibited colony formation and migration, and synergistically inhibited viability in colorectal cancer cell lines harboring BRAF V600E in culture and increased tumor growth inhibition in cell line and patient-derived xenograft (PDX) models compared to either drug alone (PMID: 40481178). | 40481178 |
| BRAF V600E | colorectal cancer | sensitive | Dasatinib + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Zelboraf (vemurafenib) and Sprycel (dasatinib) synergistically inhibited viability in colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 36759733). | 36759733 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36759733) | A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. | Full reference... |
| (40481178) | Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. | Full reference... |